<DOC>
	<DOCNO>NCT02092181</DOCNO>
	<brief_summary>The purpose study see study drug , Mirabegron , safe effective treating symptom Overactive Bladder people Parkinson 's Disease .</brief_summary>
	<brief_title>A Pilot Study Mirabegron Behavioral Modification Including Pelvic Floor Exercise Overactive Bladder Parkinson 's Disease ( MAESTRO )</brief_title>
	<detailed_description>This study randomize 1:1 placebo-controlled 10-week study Mirabegron add-on therapy educational intervention behavioral modification include pelvic floor exercise ( PFE ) cohort 40 Parkinson 's subject age 30 overactive bladder ( OAB ) . Active drug Mirabegron 25 mg daily up-titration 50 mg daily 5 week . Subjects enrol base response overactive bladder questionnaire visit 2 . Enrolled subject 4 study visit clinic well 2 phone visit . Enrolled subject ask record urinary symptom pelvic floor exercise diary 3 separate time point 72 hour period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Diagnosis Parkinsons United Kingdom brain bank criterion Age &gt; 30 year old No change Parkinsons medication 4 week precede screening , dose change study , except PRN ( need ) dose carbidopa/levodopa allow address periodic worsen parkinsonian symptom . Patient willing able complete micturition diary Urinary urgency ( ≥ 8 entry bladder urgency score &gt; 2 ) 72hr void diary screening period Micturition frequency ≥ 8 / 24hr incontinence ≥ 2 episode 72hr void diary screening period Use medication could influence bladder function , specifically prohibit ( see ) , permit long dose stable 4 week precede screening , dose change study . Patient expect valid health insurance duration study period Women breastfeeding , pregnant potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) . Cognitive deficit opinion investigator would interfere subject 's ability give inform consent perform study test . Screening blood pressure &gt; 165 systolic 100 diastolic Heart rate &gt; 100 History allergy Mirabegron . Screening postvoid residual &gt; 200ml Evidence urinary tract infection screen History chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy , previous current malignant disease pelvic organs Intravesical botulinum toxin treatment within previous six month screen . Presence Interstim device Use indwelling catheter selfcatheterization Concurrent use thioridazine , flecainide , propafenone , Digoxin Concurrent use warfarin ( Coumadin ) Use one anticholinergic bladder medication specify within 14 day screen visit . Subjects use one medication past discontinue least 14 day prior screen visit enrol . Screening estimate glomerular filtration rate ( eGFR ) &lt; 60 , AST ( aspartate aminotransferase ) ALT ( alanine aminotransferase ) &gt; 2x upper limit normal Any serious and/or unstable medical condition Participation drug study use investigational drug within 30 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>